Neoadjuvant fruquintinib plus tislelizumab and mCapeOX for pMMR/MSS locally advanced rectal cancer: Safety lead-in results of a prospective, randomized, multicenter trial (ESMO Asia 2026) - Oct 1, 2026 - Abstract #178P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • pMMR • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor
|
|
Xiaokang Lei; Aiwen Wu; Lin Wang; Yingjie Li; Xiaoyan Zhang; Yuzhuo Guo
|